Circulating filarial antigen detection in brugian filariasis

Parasitology ◽  
2015 ◽  
Vol 143 (3) ◽  
pp. 350-357
Author(s):  
PRAVEEN KUMAR TRIPATHI ◽  
RAMESH CHANDER MAHAJAN ◽  
NANCY MALLA ◽  
ABHISHEK MEWARA ◽  
SHAILJA MISRA BHATTACHARYA ◽  
...  
Keyword(s):  
Adult Worm ◽  
Specific Antigen ◽  
Antigen Detection ◽  
Serum Samples ◽  
Helminthic Infections ◽  
Filarial Antigen ◽  
Endemic Normal ◽  
Grade Iii ◽  
Antigen Reactivity ◽  
Circulating Filarial Antigen

SUMMARYHuman lymphatic filariasis (LF) is a major cause of disability globally. The success of global elimination programmes for LF depends upon effectiveness of tools for diagnosis and treatment. In this study on stage-specific antigen detection in brugian filariasis, L3, adult worm (AW) and microfilarial antigenaemia were detected in around 90–95% of microfilariae carriers (MF group), 50–70% of adenolymphangitis (ADL) patients, 10–25% of chronic pathology (CP) patients and 10–15% of endemic normal (EN) controls. The sensitivity of the circulating filarial antigen (CFA) detection in serum samples from MF group was up to 95%. In sera from ADL patients, unexpectedly, less antigen reactivity was observed. In CP group all the CFA positive individuals were from CP grade I and II only and none from grade III or IV, suggesting that with chronicity the AWs lose fecundity and start to disintegrate and die. Amongst EN subject, 10–15% had CFA indicating that few of them harbour filarial AWs, thus they might not be truly immune as has been conventionally believed. The specificity for antigen detection was 100% when tested with sera from various other protozoan and non-filarial helminthic infections.

scholarly journals Occurrence ofBordetellaInfection in Pigs in Northern India

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Sandeep Kumar ◽  
Bhoj R. Singh ◽  
Monika Bhardwaj ◽  
Vidya Singh
Keyword(s):  
Plasmid Profile ◽  
Antigen Detection ◽  
Bordetella Bronchiseptica ◽  
Atrophic Rhinitis ◽  
Serum Samples ◽  
Northern India ◽  
Antimicrobial Sensitivity ◽  
Nasal Swabs ◽  
Species Specific ◽  
Almost All

Bordetella bronchisepticainfection causing atrophic rhinitis in pigs is reported from almost all countries. In the present study, occurrence ofBordetellainfection in apparently healthy pigs was determined in 392 pigs sampled to collect 358 serum samples and 316 nasal swabs from Northern India by conventional bacterioscopy, detection of antigen with multiplex polymerase chain reaction (mPCR), and detection of antibodies with microagglutination test (MAT) and enzyme linked immune-sorbent assay (ELISA).Bordetella bronchisepticacould be isolated from six (1.92%) nasal swabs. Although isolates varied significantly in their antimicrobial sensitivity, they had similar plasmid profile. The genus specific and species specific amplicons were detected from 8.2% and 4.4% nasal swabs using mPCR withalcgene (genus specific) andflagene andfim2 gene (species specific) primers, respectively. Observations revealed that there may be other bordetellae infecting pigs because about 50% of the samples positive using mPCR for genus specific amplicons failed to confirm presence ofB. bronchiseptica. Of the pig sera tested with MAT and ELISA forBordetellaantibodies, 67.6% and 86.3% samples, respectively, were positive. For antigen detection mPCR was more sensitive than conventional bacterioscopy while for detection of antibodies neither of the two tests (MAT and ELISA) had specificity in relation to antigen detection. Study indicated high prevalence of infection in swine herds in Northern India.

scholarly journals Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2

2004 ◽  
Vol 50 (9) ◽  
pp. 1607-1617 ◽  
Author(s):  
Ville Väisänen ◽  
Susann Eriksson ◽  
Kaisa K Ivaska ◽  
Hans Lilja ◽  
Martti Nurmi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Detection Limit ◽  
Solid Phase ◽  
Specific Antigen ◽  
Control Group ◽  
Serum Samples ◽  
Human Kallikrein 2 ◽  
Kallikrein 2 ◽  
Capture Antibody ◽  
Total Psa

Abstract Background: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostate cancer and benign prostatic hyperplasia. Concentrations of hK2 are 100-fold lower than concentrations of prostate-specific antigen (PSA); therefore, an hK2 assay must have a low detection limit and good specificity. Methods: PSA- and hK2-specific monoclonal antibodies were used in solid-phase, two-site immunofluorometric assays to detect free and total hK2. The total hK2 assay used PSA-specific antibodies to block nonspecific signal. The capture antibody of the free hK2 assay did not cross-react with PSA. To determine the hK2 concentrations in the male bloodstream, total hK2 was measured in a control group consisting of 426 noncharacterized serum samples. Free and total hK2 were measured in plasma from 103 patients with confirmed prostate cancer. Results: All 426 males in the control group had a total hK2 concentration above the detection limit of 0.0008 μg/L. The median total hK2 concentration was 0.022 μg/L (range, 0.0015–0.37 μg/L). hK2 concentrations were 0.1–58% of total PSA (median, 3.6%). hK2 concentrations were similar in men 41–50 and 51–60 years of age. The ratio of hK2 to PSA steadily decreased from 5–30% at PSA <1 μg/L to 1–2% at higher PSA concentrations. In 103 patients with prostate cancer, the median hK2 concentration in plasma was 0.079 μg/L (range, 0.0015–16.2 μg/L). The median free hK2 concentration was 0.070 (range, 0.005–12.2) μg/L. The proportion of free to total hK2 varied from 17% to 131% (mean, 85%). Conclusions: The wide variation in the free-to-total hK2 ratio suggests that hK2 in blood plasma is not consistently in the free, noncomplexed form in patients with prostate cancer. The new assay is sufficiently sensitive to be used to study the diagnostic accuracies of free and total hK2 for prostate cancer.

Real-time prostate-specific antigen detection with prostate-specific antigen imprinted capacitive biosensors

2015 ◽  
Vol 891 ◽  
pp. 120-129 ◽  
Author(s):  
Gizem Ertürk ◽  
Martin Hedström ◽  
M. Aşkın Tümer ◽  
Adil Denizli ◽  
Bo Mattiasson
Keyword(s):  
Real Time ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Antigen Detection

scholarly journals Quantification of a Proteotypic Peptide from Protein C Inhibitor by Liquid Chromatography–Free SISCAPA-MALDI Mass Spectrometry: Application to Identification of Recurrence of Prostate Cancer

2013 ◽  
Vol 59 (10) ◽  
pp. 1514-1522 ◽  
Author(s):  
Morteza Razavi ◽  
Lisa DS Johnson ◽  
Julian J Lum ◽  
Gary Kruppa ◽  
N Leigh Anderson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Liquid Chromatography ◽  
High Throughput ◽  
Protein C ◽  
Specific Antigen ◽  
Serum Concentrations ◽  
Serum Samples ◽  
Biomarker Validation ◽  
Protein C Inhibitor ◽  
Proteotypic Peptide

BACKGROUND Biomarker validation remains one of the most challenging constraints to the development of new diagnostic assays. To facilitate biomarker validation, we previously developed a chromatography-free stable isotope standards and capture by antipeptide antibodies (SISCAPA)-MALDI assay allowing rapid, high-throughput quantification of protein analytes in large sample sets. Here we applied this assay to the measurement of a surrogate proteotypic peptide from protein C inhibitor (PCI) in sera from patients with prostate cancer. METHODS A 2-plex SISCAPA-MALDI assay for quantification of proteotypic peptides from PCI and soluble transferrin receptor (sTfR) was used to measure these peptides in 159 trypsin-digested sera collected from 51 patients with prostate cancer. These patients had been treated with radiation with or without neoadjuvant androgen deprivation. RESULTS Patients who experienced biochemical recurrence of prostate cancer showed decreased serum concentrations of the PCI peptide analyte within 18 months of treatment. The PCI peptide concentrations remained increased in the sera of patients who did not experience cancer recurrence. Prostate-specific antigen concentrations had no predictive value during the same time period. CONCLUSIONS The high-throughput, liquid chromatography–free SISCAPA-MALDI assay is capable of rapid quantification of proteotypic PCI and sTfR peptide analytes in complex serum samples. Decreased serum concentrations of the PCI peptide were found to be related to recurrence of prostate cancer in patients treated with radiation with or without hormone therapy. However, a larger cohort of patients will be required for unequivocal validation of the PCI peptide as a biomarker for clinical use.

Analysis, characterization and diagnostic use of circulating filarial antigen in bancroftian filariasis

1990 ◽  
Vol 15 (1) ◽  
pp. 37-46 ◽  
Author(s):  
K. A. Parkhe ◽  
M. V. R. Reddy ◽  
K. Cheirmaraj ◽  
P. Ramaprasad ◽  
B. C. Harinath
Keyword(s):  
Bancroftian Filariasis ◽  
Diagnostic Use ◽  
Filarial Antigen ◽  
Circulating Filarial Antigen
Sign in / Sign up

Export Citation Format

Share Document